NRG-BR008, The "HERO" Breast Cancer Trial

from The NRG Oncology Podcast · host NRG Oncology

The NRG Oncology Podcast Co-hosts sit with NRG-BR008 "HERO" Study Co-PIs Dr. Lior Braunstein and Dr. Melissa Mitchell to discuss this study for low-risk HER2+ breast cancer. This study will test if HER2-targeted therapy without radiation therapy is as good as the usual treatment of HER2-targeted therapy with radiation for patients with early-stage HER2+ breast cancer.

Episode metadata supplied by the publisher feed · Published Feb 5, 2025

Embed this episode

Attribution link and audio player

NOW PLAYING

NRG-BR008, The "HERO" Breast Cancer Trial

0:00 18:48

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of The NRG Oncology Podcast?

This episode is 18 minutes long.

When was this The NRG Oncology Podcast episode published?

This episode was published on February 5, 2025.

Can I download this The NRG Oncology Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!